Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;6(8):882-887.
doi: 10.1158/2326-6066.CIR-18-0066.

Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Affiliations
Review

Treg Fragility: A Prerequisite for Effective Antitumor Immunity?

Abigail E Overacre-Delgoffe et al. Cancer Immunol Res. 2018 Aug.

Abstract

Inhibitory checkpoint blockade has significantly improved patient response rate across numerous tumor types. However, most patients remain unresponsive to immunotherapy, suggesting that unappreciated mechanisms of resistance exist. The tumor microenvironment (TME) is unique and composed of many suppressive cell populations that inhibit antitumor immune responses, including regulatory T cells (Tregs). The TME is nutrient poor, acidic, and hypoxic, creating a challenging microenvironment for immune cells to function and survive. Tregs suppress a wide variety of cell populations through multiple mechanisms and are tasked with limiting tissue damage. Tregs are now considered to be a barrier to effective antitumor immunity. Systemic Treg depletion is not favored because of their critical role in maintaining immune homeostasis and preventing autoimmunity. Reducing Treg function specifically within the TME may provide a more effective, targeted approach to limit the immunosuppressive environment within the tumor without inducing systemic adverse consequences. Targeting molecules that cause Treg instability, characterized by loss of critical Treg transcription factors such as Foxp3, could result in conversion into cells that cause immune pathology, tissue damage, and subsequent autoimmune side effects. Interferon-γ (IFNγ) can cause intratumoral Treg "fragility," which results in loss of suppressive activity and increased IFNγ production without loss of Foxp3 expression and gross Treg "identity." We reviewed the impact Tregs have on the TME and vice versa, and their implications for responsiveness to cancer immunotherapy. We propose that the extent to which intratumoral Tregs develop a "fragile" phenotype following immunotherapy will predict and dictate responsiveness. Cancer Immunol Res; 6(8); 882-7. ©2018 AACR.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

D.A.A.V. declares competing financial interests. He has submitted patents that are pending or granted that cover NRP1, LAG3 and IL35, and is entitled to a share in net income generated from licensing of these patent rights for commercial development.

Figures

Figure 1
Figure 1
Contributing factors of stable, fragile, and unstable Tregs. Stable Tregs: hypomethylated at CNS2 and express other stabilizing markers like Nrp1 and Helios. Fragile Tregs: secrete IFNγ while maintaining Foxp3 expression. Unstable Tregs: loss Foxp3 expression and secrete pro-inflammatory cytokines.

References

    1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6. - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010;363(8):711–23. doi: 10.1056/NEJMoa1003466. - DOI - PMC - PubMed
    1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012;366(26):2443–54. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed
    1. Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. The FEBS journal. 2016;283(14):2731–48. doi: 10.1111/febs.13656. - DOI - PubMed
    1. Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. International immunology. 2000;12(8):1145–55. - PubMed

Publication types